Professional
Added to YB: 2024-04-22
Pitch date: 2024-04-08
ALNY [bullish]
Alnylam Pharmaceuticals, Inc.
+152.8%
current return
Author Info
No bio for this author
Company Info
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
Market Cap
$59.3B
Pitch Price
$157.26
Price Target
235.00 (-41%)
Dividend
N/A
EV/EBITDA
153.82
P/E
1.4K
EV/Sales
18.50
Sector
Biotechnology
Category
special_situation
RBC Capital Markets Investment Thesis: Alnylam Pharmaceuticals, Inc.
ALNY: Confident in HELIOS-B TTR-CM trial despite CRL for Onpattro label expansion. Rich catalyst calendar: HELIOS-B topline in June/July, P2 KARDIA-2 hypertension combo data, P1 AD results. Fundamentally attractive with M&A optionality. $235 PT on DCF (10% WACC, 1% TGR). Risks: TTR-CM failure, competition, delayed profitability.
Read full article (2 min)